Bolusing frequency and amount impacts glucose control during hybrid closed-loop. by Bally, L et al.
Short Report: Treatment
Bolusing frequency and amount impacts glucose control
during hybrid closed-loop
L. Bally1,2,3,*, H. Thabit1,2,* , Y. Ruan 1,4, J. K. Mader5, H. Kojzar5, S. Dellweg6, C. Benesch6,
S. Hartnell2, L. Leelarathna7 , M. E. Wilinska1,4, M. L. Evans1,2, S. Arnolds6, T. R. Pieber5 and
R. Hovorka1,4
1Wellcome Trust–MRC Institute of Metabolic Science, University of Cambridge, 2Department of Diabetes & Endocrinology, Cambridge University Hospitals NHS
Foundation Trust, Cambridge, UK, 3Department of Diabetes & Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital, University of
Bern, Bern, Switzerland, 4Department of Paediatrics, University of Cambridge, Cambridge, UK, 5Department of Internal Medicine, Division of Endocrinology &
Diabetology, Medical University of Graz, Graz, Austria, 6Profil Institut fuer Stoffwechselforschung GmbH, Neuss, Germany and 7Central Manchester University
Hospitals NHS foundation Trust and University of Manchester, Manchester, UK
Accepted 25 July 2017
Abstract
Aim To compare bolus insulin delivery patterns during closed-loop home studies in adults with suboptimally [HbA1c
58–86 mmol/mol (7.5%–10%)] and well-controlled [58 mmol/mol (< 7.5%)] Type 1 diabetes.
Methods Retrospective analysis of daytime and night-time insulin delivery during home use of closed-loop over
4 weeks. Daytime and night-time controller effort, defined as amount of insulin delivered by closed-loop relative to usual
basal insulin delivery, and daytime bolus effort, defined as total bolus insulin delivery relative to total daytime insulin
delivery were compared between both cohorts. Correlation analysis was performed between individual bolus behaviour
(bolus effort and frequency) and daytime controller efforts, and proportion of time spent within and below sensor
glucose target range.
Results Individuals with suboptimally controlled Type 1 diabetes had significantly lower bolus effort (P = 0.038) and
daily bolus frequency (P < 0.001) compared with those with well-controlled diabetes. Controller effort during both
daytime (P = 0.007) and night-time (P = 0.005) were significantly higher for those with suboptimally controlled Type 1
diabetes. Time when glucose was within the target range (3.9–10.0 mmol/L) during daytime correlated positively with
bolus effort (r = 0.37, P = 0.016) and bolus frequency (r = 0.33, P = 0.037). Time when glucose was below the target
range during daytime was comparable in both groups (P = 0.36), and did not correlate significantly with bolus effort
(r = 0.28, P = 0.066) or bolus frequency (r = –0.21, P = 0.19).
Conclusion More frequent bolusing and higher proportion of insulin delivered as bolus during hybrid closed-loop use
correlated positively with time glucose was in target range. This emphasises the need for user input and educational
support to benefit from this novel therapeutic modality.
Diabet. Med. 35, 347–351 (2018)
Introduction
The need for optimal glycaemic control to avoid diabetes-
related complications is well established [1,2]. Efforts to
tighten glycaemic control, however, often result in increased
risk of hypoglycaemia [3]. Closed-loop insulin delivery is an
emerging diabetes technology that has the potential to
address the unmet clinical need for improved glucose
control while reducing the burden of hypoglycaemia and
self-care in Type 1 diabetes [4]. Closed-loop use during
free-living unsupervised condition across various patient
populations with Type 1 diabetes has been shown to be
efficacious [5–8], and demonstrated greater benefits of
closed-loop during night-time compared with daytime.
The hybrid closed-loop approach in these studies employs
manual administration of a pre-meal bolus to mitigate
delayed absorption of rapid-acting insulin analogues. We
hypothesised that bolusing behaviour may impact daytime
glucose control. The aim of the analysis is to compare insulin
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delivery patterns from two previous closed-loop home
studies in adults with suboptimally controlled (group 1) [6]
and well-controlled (group 2) Type 1 diabetes [9].
Methods
We retrospectively analysed daytime (07:00 to 23:00) and
night-time (23:00 to 07:00) insulin delivery in partici-
pants who used closed-loop at least 85% of the time over
4 weeks from two separate closed-loop home studies (Clin-
icalTrials.gov registration numbers NCT01961622 [6] and
NCT02727231 [9]). The inclusion and exclusion criteria
were similar for both study groups, with the exception of
HbA1c 58–86 mmol/mol (7.5%–10%) in group 1, and
< 58 mmol/mol (< 7.5%) in group 2. The closed-loop system
used in both studies was identical comprising Dana
Diabecare R insulin pump (Sooil, Seoul, South Korea),
FreeStyle Navigator II continuous glucose monitor (Abbott
Diabetes Care, Alameda, CA, USA) and model predictive
controller (University of Cambridge, UK) residing on a
smartphone (Galaxy S4, Samsung, South Korea) communi-
cating wirelessly with continuous glucose monitoring recei-
ver through a purpose made translator unit (Triteq,
Hungerford, UK). Daytime and night-time controller effort,
defined as the amount of insulin delivered by closed-loop
relative to usual basal insulin delivery, and daytime bolus
effort, defined as total bolus insulin delivery relative to total
daytime insulin delivery were calculated.
Group 1 and group 2 data were contrasted using an
independent sample t-test. Correlation analysis was per-
formed between individual bolus behaviour (bolus effort and
frequency) and daytime controller efforts, proportion of time
spent within (3.9–10.0 mmol/L) and below sensor glucose
target range. Outcomes were calculated using GStat soft-
ware, version 2.2.4 (University of Cambridge, UK) and
statistical analyses were performed using SPSS version 23
(IBM Software, Winchester, UK). Data are reported as mean
(SD); P-values < 0.05 were considered statistically significant.
Results
Data from 459 days and 701 nights from group 1 (N = 32),
and 421 days and 579 nights from group 2 (N = 29) were
analysed. Baseline characteristics for group 1 and group 2
were: HbA1c 69 (7) mmol/mol [8.4 (0.6)%] vs. 52 (5) mmol/
mol [6.9 (0.5)%], P < 0.001; female : male 15 : 17 vs.
15 : 14, age 40 (19) vs. 41 (13) years, P = 0.81; BMI
25.4 (4.4) vs. 25.1 (3.0) kg/m2, P = 0.76; duration of dia-
betes 21 (9) vs. 24 (12) years, P = 0.32; duration of pump
use 8 (6) vs. 6 (4) years, P = 0.20; and pre-study total daily
insulin 0.61 vs. 0.53 U/kg/day, P = 0.036.
Group 1 had a significantly lower bolus effort [53 (8) vs.
59 (11)%, P = 0.038] and daily bolus frequency [4.7 (1.1)
vs. 6.0 (1.5), P < 0.001] compared with group 2 (Table 1).
This was accompanied by significantly higher controller
efforts during both daytime and night-time for group 1
compared with group 2 [daytime: 120 (22) vs. 104 (14)%,
P = 0.007; night-time: 161 (39) vs. 135 (26)%, P = 0.005].
Proportion of time spent in sensor glucose target range
during the daytime period correlated positively with bolus
effort (r = 0.37, P = 0.016; Fig. 1) and bolus frequency
(r = 0.33, P = 0.037). Time spent below sensor glucose
target range during daytime was comparable in both groups
(P = 0.36), and did not correlate significantly with bolus
effort (r = 0.28, P = 0.066) or bolus frequency (r = –0.21,
P = 0.19). There was a trend towards an inverse relationship
between mean glucose and (i) bolus frequency (r = –0.23,
P = 0.082) and (ii) bolus effort (r = –0.29, P = 0.062). For
each bolus, there was a trend for an associated reduction in
mean glucose of 0.21 mmol/L (P = 0.082). Overall and
night-time variability in insulin requirements were compara-
ble between group 1 and group 2.
Discussion
The result of this retrospective analysis shows that hybrid
closed-loop users with well-controlled Type 1 diabetes have
higher bolusing frequency and total amount of self-adminis-
tered bolus insulin relative to total daytime insulin, com-
pared with those with suboptimally controlled diabetes. This
bolusing behaviour was associated with greater time spent
within the glucose target range. However, no relationship
was found between greater bolusing efforts and behaviour,
with time spent below target glucose range.
Previously published day-and-night closed-loop home
studies have shown that the magnitude of glucose outcome
improvements during the daytime period was less pro-
nounced compared to the overnight period [6,10,11]. This
is likely due to meal-time glycaemic excursions and physical
activity related changes in insulin sensitivity, and limitations
of closed-loop performance imposed by currently available
rapid-acting insulin pharmacokinetics and the lag in inter-
stitial fluid glucose appearance [12]. Meal-announcements to
the closed-loop control algorithm and meal-time insulin
bolusing, such as that in a hybrid closed-loop system, may
partly mitigate against post-meal glycaemic excursions.
However, such user-driven input is dependent on compli-
ance and appropriate self-management behaviours by the
What’s new?
• Glucose control during hybrid closed-loop therapy is
linked to bolusing behaviour.
• Closed-loop users with well-controlled Type 1 diabetes
bolused more frequently without increasing the risk of
hypoglycaemia.
• We highlight the importance of user input and educa-
tion to gain optimal benefit from hybrid closed-loop.
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user, to avoid post-meal hyperglycaemia and/or delayed
hypoglycaemia. A recent study evaluating the relationship
between behavioural patterns and glucose control (mean
glucose, glucose variability and post-intervention HbA1c)
during hybrid closed-loop use in suboptimally controlled
Type 1 diabetes highlighted the impact behavioural patterns,
such as eating habits, have on glucose control [13]. In line
with the present study, no significant association was found
between bolusing frequency and mean glucose. However,
these relationships were not explored in well-controlled
Type 1 diabetes individuals at increased risk of hypogly-
caemia [HbA1c <58 mmol/mol (< 7.5%)]. The need to self-
administer insulin boluses for meals may also not match
user’s initial expectation of an ‘artificial pancreas’, or as an
approach to lessen their self-management burden [14].
Potential alternative approaches include ultrafast-acting
insulin [15], adjuvants such as amylin which delays meals
absorption [16], or local warming devices to enhance insulin
absorption [17]. Prior to adopting these approaches into
wider clinical practice, large-scale studies are still needed to
demonstrate their clinical efficacy and user acceptability. The
first commercially available closed-loop system recently
approved by the US Food and Drug Administration adopts
the hybrid approach [18]. As such, hybrid closed-loop
remains at present a pragmatic and well-studied therapeutic
approach for bringing closed-loop into clinical practice.
Owing to the requirement for on-going user input and
interaction with the system, however, there is a continuing
need for education and training in this novel technology to
help manage user expectations and gain optimal benefit in
clinical practice [14].
Intensive insulin therapy and tight glycaemic control are
associated with increased hypoglycaemia risk [3]. In daily
practice, this may be due, in part, to insulin boluses related to
meals or corrections, which were over-estimated or ill-timed
[19]. In the present analysis, time spent below target was
found to be comparable between two cohorts, despite the
relatively higher bolusing frequency in the cohort with lower
HbA1c. The autonomous modulation of insulin delivery by
closed-loop control algorithm in a glucose-responsive man-
ner, which also accounts for events having a protracted
influence on glycaemia such as manually delivered meal-time
and correction boluses [4], highlights the advantage of
closed-loop use compared to conventional insulin therapy.
The strength of this analysis is the large dataset of hybrid
closed-loop use available during unsupervised free-living
conditions over 4 weeks, from two Type 1 diabetes cohorts
with different glycaemic control levels. This allows for
characterisation and assessment of bolusing behaviours from
these two cohorts, during unbiased real-world use of hybrid
FIGURE 1 Correlation between % time spent in target range during the
daytime period and bolus effort.
Table 1 Characteristics of insulin delivery and glucose control during closed-loop insulin delivery in suboptimally controlled (group 1, screening
HbA1c > 58 mmol/mol or 7.5%) and well-controlled (group 2, screening HbA1c < 58 mmol/mol or 7.5%) Type 1 diabetes
Suboptimally controlled
Group 1
Well-controlled
Group 2 P-value
Daytime time in target range, 3.9–10mmol/l (%) 67 (11) 75 (7) 0.008
Daytime time below target range (%) 2.4 (1.0–4.4) 2.8 (2.0–4.8) 0.29
Bolus effort per 24 h period (%) 53 (8) 59 (11) 0.038
Bolus frequency per 24 h (n) 4.7 (1.1) 6.0 (1.5) < 0.001
Controller effort (%)
Night-time (23:00 to 07:00) 161 (39) 135 (26) 0.005
Daytime (07:00 to 23:00) 120 (22) 104 (14) 0.007
CV of insulin requirements night-time (%) 33 (8) 33 (7) 0.76
CV of insulin requirements 24 h period (%) 17 (4) 17 (3) 0.86
Data are calculated from participants who used closed-loop for at least 85% of the time and are presented as mean (SD) or median
(interquartile range). Daytime: n = 22 (group 1) and n = 21 (group 2); night-time: n = 31 (group 1) and n = 27 (group 2); 24-h period:
n = 24 (group 1) and n = 21 (group 2).
Bolus effort = proportion of total bolus insulin relative to total daily insulin during the daytime from 07:00 to 23:00.
Controller effort = proportion of insulin amount delivered by closed-loop relative to usual basal insulin amount.
Insulin requirements = proportion of total daily insulin requirements (bolus and closed-loop delivery) relative to usual total daily dose.
CV, coefficient of variation.
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closed-loop. The hybrid closed-loop systems used in both
studies were similar, thereby enabling the differences
between user-driven behaviours to be analysed independent
of the system used. The analysis of bolusing behaviour was
limited by the lack of distinction between boluses which were
meal-related, or solely as corrections for elevated glucose
levels. Bolus calculator use, carbohydrate-counting skills and
activity levels between the two groups may have differed,
thereby possibly confounding the results. The data pertaining
to overall bolusing frequency and efforts, however, underline
the importance of bolusing behaviour to the benefits and
glycaemic outcome of hybrid closed-loop. Reliable data
related to meal sizes and physical activity were not available,
and are not reported.
In conclusion, the benefit of hybrid closed-loop during the
daytime period is associated with bolusing behaviour by
users. It is of importance to emphasise user input and
education, if the benefit from hybrid closed-loop application
is to be optimised in clinical practice.
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